SPY756.60−0.42%QQQ684.96−0.78%BTC/USD73,734.50+0.05%DIA524.02−0.08%GLD365.30+0.04%TLT80.88−0.05%

Lucid Diagnostics Inc

LUCDNASDAQ

Trade with Public

$0.3814

-0.0186-4.65%

Last update: Nov 11, 5:25 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Earnings: Q3 2026 earnings tomorrow on Thu Nov 12th before the market open

Conference Call: Conference call scheduled tomorrow at 8:30 AM

Click to view the webcast

Lucid Diagnostics (LUCD) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Lucid Diagnostics (LUCD) stock.

Analyst Consensus — 6 Analysts

6Buy

# Analysts6

Latest Upgrades and Downgrades for Lucid Diagnostics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	BTIG	Mark Massaro	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$10
—	BTIG	Mark Massaro	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$9
—	Maxim Group	Anthony Vendetti	PT Cut	Buy	$3→$2
—	BTIG	Mark Massaro	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$9
—	BTIG	Mark Massaro	Maintained	Buy	$3
—	Needham	Mike Matson	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
—	Needham	Mike Matson	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
—	BTIG	Mark Massaro	Maintained	Buy	$3
—	BTIG	Mark Massaro	PT Raise	Buy	$2→$3
—	Needham	Mike Matson	Maintained	Buy	$3
—	Needham	Mike Matson	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
—	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$2
—	Needham	Mike Matson	Maintained	Buy	$3
—	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$8

Lucid Diagnostics Inc

Lucid Diagnostics (LUCD) Stock Price Target 2026

Latest Upgrades and Downgrades for Lucid Diagnostics Stock

Lucid Diagnostics (LUCD) Stock Price Target 2026

Latest Upgrades and Downgrades for Lucid Diagnostics Stock

Analyst Ratings News

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

People Also Watch

People Also Watch

Analyst Ratings News

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

Lucid Diagnostics Inc

Lucid Diagnostics (LUCD) Stock Price Target 2026

Latest Upgrades and Downgrades for Lucid Diagnostics Stock

Lucid Diagnostics (LUCD) Stock Price Target 2026

Latest Upgrades and Downgrades for Lucid Diagnostics Stock

Analyst Ratings News

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

People Also Watch

People Also Watch

Analyst Ratings News

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25